Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCC
CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about exciting trials in the head and neck space, including the phase 2 ORATER2 and phase 3 MC1675 trials.
At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about the most exciting clinical research presented at the meeting. One such trial was the phase 2 ORATER2 study (NCT03210103), which set out to assess treatment de-escalation with radiotherapy vs trans-oral surgery (TORS) in patients with human papilloma virus (HPV)–positive oropharyngeal cancer. Additionally, he highlighted the phase 3 MC1675 trial (NCT02908477), examining de-escalated adjuvant radiation therapy in HPV-associated oropharyngeal cancer.
Transcript:
In the head and neck area, there are a lot of really [interesting studies] that are going on. Specifically, [there are] 2 de-escalation trials [that I’m] excited to hear about. One is from Daniel Ma, MD. He has a phase 3 dynamic adaptive radiation therapy trial [where] they’re really looking at the de-escalation of radiation therapy after TORS for patients with HPV-positive oropharynx cancer, as compared with standard of care adjuvant radiation doses. I’m excited to hear about that.1 Also, David Palma, MD, MSc, PhD, FRCPC is going to present his phase 2 ORATOR2 trial, which actually [includes] 2 different de-escalated arms in regard to radiation as well as a surgical arm.2 There’s a lot of cool stuff coming in the field there.
References
1. Ma DJ, Price K, Eric MJ, et al. Long-term results for MC1273, a phase II evaluation of de-escalated adjuvant radiation therapy for human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC). Int J Radiat Oncol Biol Phys. 2021; 111 (suppl 3): S61. doi/10.1016/j.ijrobp.2021.07.155
2. Nichols AC, Lang P, Prisman E, et al. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2). Presented at the 2021 American Society For Radiation Oncology October 24-27. Virtual. Abstract CT01
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
